BioNTech
BNTX
264 hedge funds and large institutions have $5B invested in BioNTech in 2022 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 75 increasing their positions, 100 reducing their positions, and 49 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 6 → 9 (+3)
1.51% more ownership
Funds ownership: 13.78% → 15.29% (+1.5%)
1% more capital invested
Capital invested by funds: $4.96B → $5B (+$44.3M)
10% less funds holding
Funds holding: 293 → 264 (-29)
25% less repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 100
31% less call options, than puts
Call options by funds: $295M | Put options by funds: $427M
51% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Temasek Holdings
Singapore
|
+$587M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$227M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$135M |
| 4 |
Flossbach Von Storch
Cologne,
Germany
|
+$45.8M |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
+$37.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$90.4M |
| 2 |
Millennium Management
New York
|
-$50.5M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$47.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$40.4M |
| 5 |
FI
Fosun International
Hong Kong,
China
|
-$37M |
BNTX Hedge Fund Activity: Q3 2022 in Review
264 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q3 2022, worth a combined $5B — up 0.89% from $4.96B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of BNTX and 24 opened new positions — a net loss of 25 holders — while 100 trimmed existing stakes and 75 added.
The largest buyer was Temasek Holdings, adding an estimated $587M. The largest seller was T. Rowe Price Associates, cutting an estimated $90.4M.
- 264 institutional investors held BioNTech (BNTX) as of Q3 2022, down from 293 in Q2 2022.
- Funds reported $5B of BioNTech stock for Q3 2022, up 0.89% quarter-over-quarter.
- 24 funds opened new BioNTech positions in Q3 2022 and 49 closed out, a net change of -25 holders.
- The largest BioNTech buyer in Q3 2022 was Temasek Holdings, an estimated $587M added.
- The largest BioNTech seller in Q3 2022 was T. Rowe Price Associates, an estimated $90.4M sold.
Based on aggregated 13F filings for Q3 2022.